Convatec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand

30 March 2017

• Advanced technology and production transfer deepens companies’ long-standing partnership within diabetes care   
  
• Dedicated to advancing new technologies for continuous insulin infusion

READING, UNITED KINGDOM (29 March 2017) – Convatec Group Plc (“Convatec”), a leading global medical products and technologies company, today announced an expansion of its manufacturing technology platform for the insulin pump therapy business at Medtronic. With this expansion, Convatec’s Unomedical subsidiary is increasing its production capabilities to sustain the range of infusion sets and insulin pump therapy solutions offered by the Diabetes Group at Medtronic.

The arrangement further deepens the companies’ long-standing partnership within diabetes care and their shared commitment to meeting the growing demand for insulin pump therapy among people with diabetes. An estimated 700,000 people worldwide, predominantly with type 1 diabetes, depend on insulin pump therapy.¹

Convatec’s Unomedical subsidiary develops, produces and supplies to Medtronic a range of disposable infusion sets, including MiniMed^® QuickSet^®, MiniMed Silhouette^®, MiniMed Sure-T^® and the MiniMed Mio^® family, used in insulin pump therapy. An infusion set is a critical component of an insulin pump system, consisting of a small tube called a cannula, typically inserted under the skin in the abdominal area, which delivers insulin from an insulin pump to the body of a person with diabetes.

“We are excited to expand our long-standing partnership with Medtronic, sharing advanced technologies and complementary competencies to ensure that we can meet the needs of the increasing number of people with diabetes who are depending on insulin pump therapy,” said John M. Lindskog, President, Infusion Devices, Convatec. “Together, we have a great foundation for offering the best solutions for people with diabetes, giving them more control and freedom in their lives.”

“We have a trusted partner in Unomedical with significant manufacturing know-how and a long track record of delivering reliable, high quality consumable components as we continue to expand our insulin pump business around the world,” added Bogdan Madzar, Vice President of R&D and Global Consumables for Diabetes Service and Solutions at Medtronic. “Together, we are advancing innovations that expand the options for people using insulin pumps as we seek to both improve outcomes and satisfy lifestyle needs so that people with diabetes can enjoy greater freedom and better health.”

Since 1997, Unomedical and Medtronic have worked in collaboration to improve the lives of people with diabetes using insulin pump therapy. As the partnership enters its third decade, the two companies are working together to develop the next generation of solutions for continuous insulin infusion

Enquiries

Convatec

Bobby Leach, VP Group Corporate Affairs, Convatec    +44 (0)7770 842 226
Kirsty Law, Director Investor Relations                              +44 (0)7470 909 582

Finsbury

Rebecca Fitchett                                                                     +44 (0)207 251 3801

About Convatec

About Convatec  Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. www.convatecgroup.com

# # #

^® indicate trademarks of Medtronic MiniMed, Inc.
© 2017 Convatec Inc.
AP-017565-GB

------------------------------------------------
1 Global Insulin Pump Market with Focus on Patch Pumps (2016 – 2020) Daedal Research, March 2016

Download PRESS RELEASE

PDF